文献速递妇科

DUO-E 试验 pMMR 子宫内膜癌生物标志物异质性与度伐利尤单抗疗效探索性分析

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.
PubMed 文献 · Gynecol Oncol · 2026-02-13

基于 III 期 DUO-E 试验 pMMR 亚组,探索性分析关键生物标志物与组织学类型及其与 PFS 的关系。pMMR 亚组 575 例中 486 例可评估标志物,84%(407 例)至少一项阳性,PD-L1 阳性(67%)与 TP53 突变(59%)最常见。多标志物及组织学亚组中两治疗组 PFS 风险比均优于对照,多数亚组中度伐利尤单抗+奥拉帕利组更优。

要点

  • pMMR 亚组生物标志物高度异质,84% 患者至少一项标志物阳性。
  • PD-L1 阳性(67%)与 TP53 突变(59%)是最常见标志物。
  • 多标志物及组织学亚组中,度伐利尤单抗+奥拉帕利 PFS 获益更优。

核心结论

  • 在 pMMR 子宫内膜癌中,度伐利尤单抗+奥拉帕利在多种生物标志物和组织学亚组中较对照改善 PFS,与主要分析一致。

研究设计与样本

  • III 期 DUO-E 试验的探索性分析,患者按 1:1:1 随机分为卡铂/紫杉醇对照、度伐利尤单抗、度伐利尤单抗+奥拉帕利三组。
  • pMMR 亚组共 575 例,其中 486 例可评估所关注生物标志物。

主要发现

  • 可评估的 486 例中 84%(407 例)至少一项标志物阳性,PD-L1 阳性占 67%,TP53 突变占 59%。
  • 标志物已知亚组中子宫内膜样组织学占 52%,浆液性占 27%。
  • 探索性分析显示,多个生物标志物及组织学已知亚组中两治疗组 PFS 风险比较对照改善。
  • 多数评估的生物标志物/组织学亚组中,度伐利尤单抗+奥拉帕利组更优。

临床怎么用

  • 提示 pMMR 子宫内膜癌生物标志物异质性高、常重叠,临床解读疗效时需结合标志物与组织学背景。

局限性

  • 为探索性分析,生物标志物仅在部分 pMMR 患者中可评估,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The phase 3 DUO-E trial demonstrated statistically significant progression-free survival (PFS) benefit with carboplatin/paclitaxel plus durvalumab followed by durvalumab with/without olaparib maintenance versus carboplatin/paclitaxel alone in advanced/recurrent endometrial cancer. We report exploratory analyses of key biomarkers and histology in the mismatch repair proficient (pMMR) subpopulation. METHODS: Patients were randomised 1:1:1 to carboplatin/paclitaxel (control arm), carboplatin/paclitaxel plus durvalumab followed by durvalumab (durvalumab arm) or carboplatin/paclitaxel plus durvalumab followed by durvalumab plus olaparib (durvalumab + olaparib arm). The presence of and relationship between selected biomarkers and histology, and PFS were investigated in the pMMR subpopulation. RESULTS: Biomarkers of interest (programmed death-ligand 1 [PD-L1] expression and mutations in BRCA1/BRCA2 genes, homologous recombination repair genes, DNA polymerase epsilon and tumour protein 53 [TP53m]) were evaluable in 486/575 patients in the pMMR subpopulation, with 84% (n = 407) positive for ≥ 1 biomarker; PD-L1 positive (67%) and TP53m (59%) were the most prevalent biomarkers. In the biomarker-known subpopulation, 52% and 27% of patients had tumours of endometrioid and serous histology, respectively. In exploratory analyses, PFS hazard ratios were improved versus control for both treatment arms across multiple biomarker and histology known subgroups, and favoured the durvalumab + olaparib arm in the majority of assessed biomarker/histological subgroups. CONCLUSIONS: The DUO-E pMMR subpopulation was highly heterogeneous with frequent overlap of biomarkers and histology. Consistent with the primary analysis, durvalumab plus olaparib improved the PFS benefit observed with durvalumab versus control across a range of biomarker and histological subgroups.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Westin SN, Moore K, Chon HS, et al. Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial. Gynecol Oncol. 2026. PMID: 41690202. doi:10.1016/j.ygyno.2026.01.777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。